643
Participants
Start Date
October 20, 2017
Primary Completion Date
October 25, 2018
Study Completion Date
October 25, 2018
Calcipotriene/Betamethasone Dipropionate
Topical suspension 0.005%/0.064% (Glenmark Pharmaceuticals Ltd)
Taclonex®
Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (LEO Pharma Inc.)
Placebo
Placebo of Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd.)
Investigational Site 29, Forest Hills
Investigational Site 28, Rochester
Investigational Site 23, Richmond
Investigational Site 31, Norfolk
Investigational Site 4, High Point
Investigational Site 27, Mt. Pleasant
Investigational Site 18, Fountain Inn
Investigational Site 7, Miramar
Investigational Site 1, Miami
Investigational Site 30, Miami
Investigational Site 22, Tampa
Investigational Site 8, Nashville
Investigational Site 9, Knoxville
Investigational Site 21, Louisville
Investigational Site 10, South Bend
Investigational Site 15, New Albany
Investigational Site 6, Ann Arbor
Investigational Site 12, Fridley
Investigational Site 26, Saint Joseph
Investigational Site 11, College Station
Investigational Site 16, San Antonio
Investigational Site 19, San Antonio
Investigational Site 5, Austin
Investigational Site 14, Denver
Investigational Site 17, Henderson
Investigational Site 25, Las Vegas
Investigational Site 32, Santa Monica
Investigational Site 24, Encinitas
Investigational Site 13, San Diego
Investigational Site 20, San Diego
Investigational Site 3, Fremont
Lead Sponsor
Glenmark Pharmaceuticals Ltd. India
INDUSTRY